Market chatter still high on InterMune takeout rumors

|By:, SA News Editor

Market buzz remains high about several pharmaceutical companies' interest in the orphan drug maker.

InterMune (ITMN) considered selling itself three years ago but no deals were reached due to uncertainty with pirfenidone data.

On February 25, the company disclosed positive trial data showing significant slowing of disease progression versus placebo. Shares gapped up 170% on a 17-fold increase in volume.

Shares are up 14% on heavy volume in today's trading.

250 mutual funds have positions.